

**FIEVE CLINICAL RESEARCH, INC.
STUDY HISTORY LOG**

Sponsor Company	Date	Therapeutic Area	Target Enrollment	# Enrolled	Protocol Title	Study Phase
Abbott	1992/02 - 1992/08	Generalized Anxiety Disorder	10	16	Double blind, flexible dose, multicenter study comparing ** with placebo in GAD	III
AstraZeneca	2006-2008	Generalized Anxiety Disorder	7	35	A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of ** compared with placebo as an adjunct to treatment in patients with generalized anxiety disorder who demonstrate partial or no response to a selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor alone or in combination with a benzodiazepine	III
AstraZeneca	2006/01 - 2007/07	Major Depressive Disorder	10	15	A Multicenter, Double-Blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of ** as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period	III
AstraZeneca	2006/01 - 2007/08	Generalized Anxiety Disorder	10	28	A Multi-center, Double-Blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of ** as Monotherapy in the Maintenance Treatment of Patients with Generalized Anxiety Disorder (GAD) Following an Open-Label Stabilization Period	III
AstraZeneca	2008/07	Generalized Anxiety Disorder	10	9	A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Phase II Proof of Concept Study of 3 Oral Dose Groups of **in Subjects with Generalized Anxiety Disorder	II
AstraZeneca	2011 - ongoing Enrollment Closed	Major Depressive Disorder	10	12	A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase III, Long-Term Safety and Tolerability Study of ** as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy	III
AstraZeneca	2011- ongoing Enrollment Closed	Major Depressive Disorder	10	15	A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of ** as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy	III
Bristol Myers Squibb	1991 - 1992	Major Depressive Disorder	20	43	Double Blind Multicenter Trial of Two Dose Ranges of ** Compared to Placebo in the Treatment of Depressed Outpatients	III
Bristol Myers Squibb	1992/10 - 1993/04	Generalized Anxiety Disorder	20	18	Double Blind, Placebo Controlled Multicenter Trial Comparing 30mg ** Given BID vs. TID in Patients with GAD	III
Bristol Myers Squibb	1993/10 - 1994/04	Major Depressive Disorder	10	10	Double Blind trial comparing ** to ** in patients with Activation side effects previously demonstrated during treatment with ** for MDD	III
Bristol Myers Squibb	1993/10 - 1994/04	Major Depressive Disorder	20	34	The Safety, Surveillance Study for ** Sustained Release in Patients with Depression	III
Bristol Myers Squibb	1993/10 - 1994/08	Major Depressive Disorder	10	10	A Multicenter Double Blind Randomized Trial comparing the effects of ** to ** on Sexual Function in patients with previously demonstrated Sexual Dysfunction with ** during treatment for MDD	III
Bristol Myers Squibb	1994/04 - 1994/11	Major Depressive Disorder	20	17	Double Blind, Placebo-Controlled, Flexible Dose Response Study of ** in Outpatients with MDD	III
Bristol Myers Squibb	2000/10 - 2001/06	Cardiovascular	8	8	** Cardiovascular Treatment Assessment Versus **	III
Bristol Myers Squibb	2004/06	Bipolar I- Depression	10	9	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ** in the Treatment of Patients with Bipolar I Disorder with a Major Depressive Episode	III

**FIEVE CLINICAL RESEARCH, INC.
STUDY HISTORY LOG**

Sponsor Company	Date	Therapeutic Area	Target Enrollment	# Enrolled	Protocol Title	Study Phase
Bristol Myers Squibb	2004/09 - 2006/11	Major Depressive Disorder	10	1	A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of ** as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Episode	III
Bristol Myers Squibb	2004/09 - 2006/11	Major Depressive Disorder	10	7	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ** as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder	III
Bristol Myers Squibb	2005/11 - 2008/01	Bipolar I- Mania	10	8	Efficacy of ** in Combination with Valproate or Lithium in the Treatment of Mania patients with Bipolar I Disorder Partially Non-responsive to Valproate or Lithium Monotherapy	III
Bristol Myers Squibb/Otsuka	2002/05 - 2002/11	Schizophrenia	5	1	A Prospective, Multicenter, Open-Label Study of ** in the Mangement of Patients with Schizophrenia or Schizoaffective Disorder in General Psychiatric Practices	III
CeNeRx Biopharma, Inc.	2008/09	Major Depressive Disorder	15	18	A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of ** 60mg TID in Subjects with Major Depressive Disorder	III
Cephalon	2002/07 - 2001/12	Major Depressive Disorder	8	19	A phase 4, multicenter, 6-week, Double-Blind, randomized, Placebo-Controlled, parallel-group study to evaluate the safety and efficiency of ** at individually titrated doses of 100, 200, 300, or 400 mg/day as adjunctive therapy in patients with Major Depression who demonstrated a partial response to antidepressant therapy	IV
Cephalon	2002/11 - 2003/07	Major Depressive Disorder	8	9	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety & Efficacy of 8 Weeks of Oral ** (200 mg Once Daily) as Adjunctive Treatment for Excessive Sleepiness in Adults with Major Depressive Disorder, Sleepiness, and Fatigue, Followed by a 12-Week Open Label Period	III
Cephalon	2003/04 - 2004/01	Generalized Anxiety Disorder	10	9	An 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of ** at Dosages up to 16mg/day, the the Treatment of Generalized Anxiety Disorder in Adults	III
Cephalon	2003/09 - 2003/10	Generalized Anxiety Disorder	7	6	A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of **, at Dosages up to 16mg/day in Adults with Generalized Anxiety Disorder	III
Cephalon	2005/01 - 2005/11	Generalized Anxiety Disorder	20	25	A 10-week, Randomized, Double-Blind, Placebo-controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of ** at 4, 8, 12 mg/day in the Treatment of Adults with Generalized Anxiety Disorder	III
DOV	2005/07	Chronic Lower Back Pain	10	8	A Multi-Center, Double-Blind, Placebo- Controlled Randomized Study of ** 200mg BID, ** 300 mg BID, and ** 400mg BID, in the Treatment of Chronic Low Back Pain	III
DOV	2005/12	Chronic Lower Back Pain	10	1	A Multi-Center, Standard of Care-Controlled Study to Evaluate the Long-Term Safety of ** for the Treatment of Chronic Low Back Pain	III
Eli Lilly	1986	Major Depressive Disorder	10	11	** vs. Placebo fixed dose study in outpatients with MDD	III
Eli Lilly	1996	Major Depressive Disorder	20	33	** vs. ** and ** in Major Depression: Comparison of Discontinuation-Emergent Signs and Symptoms.	III
Eli Lilly	1989 - 1990	Major Depressive Disorder	20	33	** vs. ** and Placebo trial in outpatients with MDD	III
Eli Lilly	1989 -1990	Major Depressive Disorder	8	3	Double blind study of fixed dose ** compared to Placebo in out patients with MDD	III
Eli Lilly	1999/10 - 2001/07	Bipolar I	15	19	** verses Placebo in the Prevention of Relapse in Bipolar Disorder	III

**FIEVE CLINICAL RESEARCH, INC.
STUDY HISTORY LOG**

Sponsor Company	Date	Therapeutic Area	Target Enrollment	# Enrolled	Protocol Title	Study Phase
EM Industries	1993/08 - 1994/08	Major Depressive Disorder	40	51	Phase II multicenter, randomized, parallel-group, dose-finding study of 3 different doses of ** vs. placebo in outpatients suffering from depression	II
Forest Laboratories	2001/04 - 2001/12	Generalized Anxiety Disorder	12	19	A Flexible dose comparison of the safety and efficiency of ** and placebo in the treatment of Generalized Anxiety Disorder	III
Forest Laboratories	2001/05 - 2001/07	Major Depressive Disorder	20	14	Flexible dose comparison of the safety and efficiency of ** and ** in the treatment of Major Depressive Disorder	II
Forest Laboratories	2001/05 - 2002/07	Generalized Anxiety Disorder	12	13	An open label extension study of the safety and efficiency of ** on patients with Generalized Anxiety Disorder	III
Forest Laboratories	2004/02 - 2004/08	Generalized Anxiety Disorder	12	11	A Double-Blind Flexible Dose Comparison of **, ** and Placebo in the Treatment of Generalized Anxiety Disorder	III
Glaxo SmithKline	1988	Generalized Anxiety Disorder	12	18	Placebo-controlled, Dose-response, Multi-Center Evaluation of the Safety and Efficacy of orally administered ** in outpatients with GAD	III
Glaxo SmithKline	1997/10 - 1999/07	Bipolar I- Depression	20	55	A Multi-center, Double-blind, Placebo-Controlled, Randomized, Fixed-Dose Evaluation of the Safety and Efficacy of ** in the Long-Term Prevention of Relapse and Recurrence of Depression in Patients with Bipolar I Disorder	III
Glaxo SmithKline	1998/01 - 1999/07	Bipolar I	12	24	A Multi-center, Double-blind, Placebo-Controlled, Randomized, Fixed-Dose Evaluation of the Safety and Efficacy of ** in the Long-Term Prevention of Relapse and Recurrence of Mania in Patients with Bipolar I Disorder	III
Glaxo SmithKline	1999/12 - 2001/02	Migraine Headache	6	4	Patient Treatment Preference for and Satisfaction with Migraine Headache Therapy: ** Tablets Verses Current (non-triptan) Therapy	III
Glaxo SmithKline	2001/06 - 2002/03	Bipolar I- Depression	20	13	A Multicenter, Double Blind, Placebo-Controlled, fixed- dose evaluation of the safety, efficacy, and tolerability of ** in the treatment of a Major Depressive Episode in patients with Type 1 Bipolar Disorder	III
Glaxo SmithKline	2002/09 - 2003/11	Seasonal Affective Disorder	6	8	A 6 1/2 Month, Multicenter, Randomized, Double-blind, Placebo-Controlled, Comparison of 150-300 mg/day of ** and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder	III
Glaxo SmithKline	2003/02 - 2004/06	Major Depressive Disorder	20	21	A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of a Once-Daily Oral ** (20-40-60mg) Versus Placebo in Subjects with Major Depressive Disorder Over an Eight-Week Treatment Period	III
Glaxo SmithKline	2003/02 - 2005/10	Bipolar I- Depression	18	26	A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of ** in the Treatment of Bipolar Disorder Patients Currently Experiencing a Major Depressive Episode	III
Glaxo SmithKline	2003/12 - 2005/10	Bipolar II	18	35	A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of ** in the Treatment of Major Depression in Patients with Type II Bipolar Disorder	III
Janssen	2002/06 - 2003/06	Treatment Resistant Depression	10	7	An Open-Label Investigation of the Effectiveness and Safety of **Augmentation of SSRI Monotherapy in Adult and Geriatric Subjects with Unipolar Treatment Resistant Depression; Followed by a Randomized, Double-Blind, Placebo-Controlled Discontinuation to Evaluate Relapse Prevention	III
Lundbeck	1992 -1993	Major Depressive Disorder	25	69	A Double blind, fixed dose, placebo controlled, multicenter study of ** vs. Placebo in outpatients with moderate to severe depression	III

**FIEVE CLINICAL RESEARCH, INC.
STUDY HISTORY LOG**

Sponsor Company	Date	Therapeutic Area	Target Enrollment	# Enrolled	Protocol Title	Study Phase
MediciNova	2005/09 - 2006/04	Generalized Anxiety Disorder	10	10	A Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of two flexible dosing regimens of **in patients with DSM-IV defined generalized Anxiety Disorder (GAD)	II
Merck	1997/08 - 1998/08	Major Depressive Disorder	30	40	A Multicenter, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of ** in Patients with Major Depressive Disorder - Single Episode or Recurrent	III
Novartis	2007/02 - 2008/08	Major Depressive Disorder	10	6	An 8 week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of ** 25mg and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension	III
Novartis	2007/02 - 2008/08	Major Depressive Disorder	10	9	An 8 week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of ** 25mg and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension	III
Organon	1995 - 1996	Major Depressive Disorder	30	59	8-week Multicenter Active and Placebo-Controlled Fixed-dose, Efficiency and Safety Study of ** in Outpatients with MDD	III
Organon	1997 - 1998	Major Depressive Disorder	30	42	A multicenter, Placebo-controlled studies of relapse prevention by long-term treatment with the recommended dose range of ** in outpatients with MDD	III
Ortho-McNeil	2002/10 - 2003/07	Major Depressive Disorder	10	3	** Verses Placebo as Add-on Treatment in Subjects with Bipolar Disorder in the Outpatient Setting	III
Ortho-McNeil	2003/02 - 2003/04	Anorexia Nervosa	2	0	The Effect of ** on Bone Mineral Density in Pediatric Subjects with Anorexia Nervosa: A Double-Blind Placebo Controlled Study	III
Otsuka	2001/08 - 2002/01	Major Depressive Disorder	20	24	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of fixed doses of Oral ** and ** in the treatment of outpatients with moderate depression	II
Otsuka	2010 - ongoing Enrollment Closed due to Sponsor's decision to discontinue trial for change in strategic direction.	Major Depressive Disorder	10	4	A Multicenter, Randomize, Double-Blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral ** Combination Therapy in Patients With Major Depressive Disorder. (Study Discontinued by Sponsor)	III
Otsuka	2010 - ongoing Enrollment Closed due to Sponsor's decision to discontinue trial for change in strategic direction.	Major Depressive Disorder	10	1	A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral **Combination Therapy in Patients With Major Depressive Disorder (Study Discontinued by Sponsor)	III
Park-Davis	1999/10 - 2001/02	Generalized Anxiety Disorder	20	77	A placebo-controlled study of ** dosed BID and TID in patients with Generalized Anxiety Disorder	III
Park-Davis	2000/01 - 2001/02	Generalized Anxiety Disorder	20	30	Open label treatment of ** dosed 200-600 mg/day for patients with Generalized Anxiety Disorder	III
Pfizer	2005/09 - 2008/12	Bipolar I- Depression	10	7	A Six-Week, Randomized, Double-blind, Multicenter, Fixed-Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral ** in Outpatients with Bipolar I Depression	III

**FIEVE CLINICAL RESEARCH, INC.
STUDY HISTORY LOG**

Sponsor Company	Date	Therapeutic Area	Target Enrollment	# Enrolled	Protocol Title	Study Phase
Pharmacia	2002/04 - 2002/10	Generalized Anxiety Disorder	12	26	** 30mg and 60mg once daily versus placebo in Generalized Anxiety Disorder. A Randomized, Double-Blind, Placebo and Buspirone-controlled, fixed-dose parallel-group multicenter study of 10 weeks (Including a 2-week single-blind placebo period)	III
Pharmacia	2002/04 - 2003/01	Generalized Anxiety Disorder	10	11	** 60mg (or 30mg) once daily in the treatment of Generalized Anxiety Disorder. An open multicenter safety study of 5 months, including a 1-month drug-free follow-up period	III
R.W. Johnson	2001/12 - 2002/08	Bipolar I- Mania	10	6	A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-week study of the safety and efficacy of two doses of ** for the treatment of Acute Manic or Mixed episodes in subjects with Bipolar I Disorder with an optional open-label extension	III
Sandoz	1991 - 1992	Generalized Anxiety Disorder	12	20	A Prospective, Multicenter, Open-Label of the Safety of ** (5.0mg- 17.5mg) in Outpatients with GAD	III
Sanofi-Aventis	2006/05 - 2008/07	Generalized Anxiety Disorder	20	20	An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating the Efficacy, Safety and Tolerability of Two Fixed Doses (100 mg and 30 mg Once Daily) of ** in Patients with Generalized Anxiety Disorder.	III
Sepracor	2007/11 - 2009/ 01	Generalized Anxiety Disorder	12	15	A Double Blind, Randomized, Placebo-Controlled, Multicenter Study Examining The Efficacy And Safety of ** in Subjects With Generalized Anxiety Disorder	III
Sepracor	2008/06 - 2009/02	Major Depressive Disorder	12	2	A Double-Blind, Randomized, Placebo-Controlled Study Examining, the Safety, Efficacy, and Tolerability of ** in Subjects with Major Depressive Disorder (including Atypical and Melancholic Features	III
SmithKline Beecham	1988	Major Depressive Disorder	8	6	Multicenter Doxepin Controlled Double-blind Study of ** in Geriatric Patients with MDD	III
SmithKline Beecham	1999/04 - 1999/10	Post Traumatic Stress Disorder	12	21	A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Measure the Safety and Efficacy of ** vs. Placebo in Patients with Post-Traumatic Stress Disorder	III
SmithKline Beecham	2000/06 - 2001/02	Major Depressive Disorder	8	9	A Seven Week, Multi-Center Study to Examine Norepinephrine Transporter Inhibition in Patients with Major Depressive Disorder Receiving ** or **	III
Takeda	2008/01 - 2009/02	Major Depressive Disorder	10	12	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of ** versus Placebo in Acute Treatment of Adults With Major Depressive Disorder	III
Takeda	2008/06 - 2009/07	Generalized Anxiety Disorder	10	5	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of ** in Acute Treatment of Adults with Generalized Anxiety Disorder	III
Takeda	2010/06 - 2011/04	Recurrent Major Depressive Disorder	Ongoing	1	A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of ** (15 and 20 mg) in Subjects With Major Depressive Disorder	III
Takeda	2010/06 - 2011/04	Recurrent Major Depressive Disorder	10	2	A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Studying Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of ** in Acute Treatment of Adults With Major Depressive Disorder	III
Wyeth	1989	Major Depressive Disorder	10	16	Double Blind, Placebo-controlled, Parallel-group dosage determination study of ** tablets in depressed outpatients	III
Wyeth	1992	Major Depressive Disorder	20	41	Double Blind Parallel group dosage comparison study of BID and TID dosage of ** in outpatients with MDD	III

**FIEVE CLINICAL RESEARCH, INC.
STUDY HISTORY LOG**

Sponsor Company	Date	Therapeutic Area	Target Enrollment	# Enrolled	Protocol Title	Study Phase
Wyeth	1990/11 - 1991/11	Generalized Anxiety Disorder	20	28	Double Blind Placebo controlled, TD dose determination study of ** in outpatients with GAD	III
Wyeth	1994 -1995	Major Depressive Disorder	20	28	** vs. ** and ** in Major Depression: Comparison of Discontinuation-Emergent Signs and Symptoms	III